Chapter 15
Pharmacotherapy of Depression and Anxiety Disorders
Dépression : Vue d’ensemble
Depression is a common mental illness that manifests as major depression, persistent depressive disorder, and bipolar I and II disorders.
It can be ...
Antidépresseurs : aperçu
Antidepressant drugs alleviate symptoms of depression by enhancing neurotransmission in the brain.
These agents are classified based on their chemical ...
Antidépresseurs : tricycliques, ISRS et IRSN
Tricyclic antidepressants, or TCAs, are first-generation antidepressants.
They block serotonin and norepinephrine reuptake transporters while inhibiting ...
Antidépresseurs : IMAO et autres agents
Monoamine oxidase inhibitors, or MAOIs, inhibit monoamine oxidase, increasing neurotransmitter levels.
Atypical antidepressants encompass drugs with ...
Maladie de Parkinson : Vue d’ensemble
Neurodegenerative disorders are progressive conditions characterized by the irreversible loss of neurons in specific brain regions.
The primary ...
Maladie de Parkinson : traitement
Parkinson's Disease or PD is a neurodegenerative disorder characterized by an imbalance between cholinergic and reduced dopaminergic neurons.
The ...
Maladie d’Alzheimer : Vue d’ensemble
Alzheimer's disease, or AD, is a neurodegenerative disorder primarily affecting older adults, causing impaired memory and cognitive decline through ...
Maladie d’Alzheimer : traitement
The goal of Alzheimer's disease or AD pharmacotherapy is to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms, ...
À PROPOS DE JoVE
Copyright © 2025 MyJoVE Corporation. Tous droits réservés.